IES20080900A2 - Chemical messenger sensor - Google Patents

Chemical messenger sensor

Info

Publication number: IES20080900A2
Authority: IE; Ireland
Prior art keywords: cyclodextrin; conducting; anionic; substrate; electrode
Prior art date: 2008-11-10

Application number

Other languages

English (en)

Inventor

John Colleran

Claire Harley

Bernadette Alcock

Carmel Breslin

Original Assignee

Nat Univ Ireland Maynooth

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-10

Filing date

2008-11-10

Publication date

2010-05-12

2008-11-10 Application filed by Nat Univ Ireland Maynooth filed Critical Nat Univ Ireland Maynooth

2008-11-10 Priority to IES20080900 priority Critical patent/IES20080900A2/en

2009-11-10 Priority to PCT/EP2009/064942 priority patent/WO2010052342A2/fr

2010-05-12 Publication of IES20080900A2 publication Critical patent/IES20080900A2/en

Links

239000000126 substance Substances 0.000 title abstract description 5
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 125
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 52
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 51
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 43
229940076279 serotonin Drugs 0.000 claims abstract description 38
239000000758 substrate Substances 0.000 claims abstract description 36
239000002322 conducting polymer Substances 0.000 claims abstract description 31
229920001940 conductive polymer Polymers 0.000 claims abstract description 31
-1 cyclodextrin macrocycle Chemical class 0.000 claims abstract description 27
235000010323 ascorbic acid Nutrition 0.000 claims abstract description 25
239000011668 ascorbic acid Substances 0.000 claims abstract description 25
229960005070 ascorbic acid Drugs 0.000 claims abstract description 24
229960003638 dopamine Drugs 0.000 claims abstract description 21
238000001514 detection method Methods 0.000 claims abstract description 11
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims abstract description 10
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims abstract description 10
229930182837 (R)-adrenaline Natural products 0.000 claims abstract description 10
229960005139 epinephrine Drugs 0.000 claims abstract description 10
229960002748 norepinephrine Drugs 0.000 claims abstract description 10
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims abstract description 10
239000002861 polymer material Substances 0.000 claims abstract description 5
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 30
125000000129 anionic group Chemical group 0.000 claims description 24
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 17
229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 claims description 16
238000000034 method Methods 0.000 claims description 15
239000002243 precursor Substances 0.000 claims description 15
YMMGRPLNZPTZBS-UHFFFAOYSA-N 2,3-dihydrothieno[2,3-b][1,4]dioxine Chemical compound O1CCOC2=C1C=CS2 YMMGRPLNZPTZBS-UHFFFAOYSA-N 0.000 claims description 12
239000000463 material Substances 0.000 claims description 12
229920000123 polythiophene Polymers 0.000 claims description 12
239000001116 FEMA 4028 Substances 0.000 claims description 10
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 10
229960004853 betadex Drugs 0.000 claims description 10
239000007864 aqueous solution Substances 0.000 claims description 6
229920000128 polypyrrole Polymers 0.000 claims description 6
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 5
229920000642 polymer Polymers 0.000 claims description 5
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 4
229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
229940097362 cyclodextrins Drugs 0.000 abstract description 4
239000002858 neurotransmitter agent Substances 0.000 abstract description 3
230000006461 physiological response Effects 0.000 abstract description 3
230000016571 aggressive behavior Effects 0.000 abstract description 2
230000036528 appetite Effects 0.000 abstract description 2
235000019789 appetite Nutrition 0.000 abstract description 2
230000036651 mood Effects 0.000 abstract description 2
230000007958 sleep Effects 0.000 abstract description 2
239000010408 film Substances 0.000 description 21
239000010931 gold Substances 0.000 description 16
229910052737 gold Inorganic materials 0.000 description 13
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 10
230000004044 response Effects 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 7
125000004122 cyclic group Chemical group 0.000 description 7
239000000203 mixture Substances 0.000 description 7
229910003460 diamond Inorganic materials 0.000 description 6
239000010432 diamond Substances 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 5
QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
239000000178 monomer Substances 0.000 description 5
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
210000004556 brain Anatomy 0.000 description 4
229910021397 glassy carbon Inorganic materials 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229910052697 platinum Inorganic materials 0.000 description 4
241000894007 species Species 0.000 description 4
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
229910052796 boron Inorganic materials 0.000 description 3
239000004020 conductor Substances 0.000 description 3
238000002484 cyclic voltammetry Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
229910002804 graphite Inorganic materials 0.000 description 3
239000010439 graphite Substances 0.000 description 3
AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 3
229910052741 iridium Inorganic materials 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
229910052762 osmium Inorganic materials 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
229910052702 rhenium Inorganic materials 0.000 description 3
229910052703 rhodium Inorganic materials 0.000 description 3
229910052707 ruthenium Inorganic materials 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000010944 silver (metal) Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229910052719 titanium Inorganic materials 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000010668 complexation reaction Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002574 poison Substances 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
GKWLILHTTGWKLQ-UHFFFAOYSA-N 2,3-dihydrothieno[3,4-b][1,4]dioxine Chemical compound O1CCOC2=CSC=C21 GKWLILHTTGWKLQ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000002019 doping agent Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000012623 in vivo measurement Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000005184 irreversible process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000002295 serotoninergic effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000010408 sweeping Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Pathology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring And Recording Apparatus For Diagnosis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

IES20080900 2008-11-10 2008-11-10 Chemical messenger sensor IES20080900A2 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
IES20080900 IES20080900A2 (en)	2008-11-10	2008-11-10	Chemical messenger sensor
PCT/EP2009/064942 WO2010052342A2 (fr)	2008-11-10	2009-11-10	Capteur de messager chimique

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IES20080900 IES20080900A2 (en)	2008-11-10	2008-11-10	Chemical messenger sensor

Publications (1)

Publication Number	Publication Date
IES20080900A2 true IES20080900A2 (en)	2010-05-12

Family

ID=42107372

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IES20080900 IES20080900A2 (en)	2008-11-10	2008-11-10	Chemical messenger sensor

Country Status (2)

Country	Link
IE (1)	IES20080900A2 (fr)
WO (1)	WO2010052342A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20170027184A (ko) *	2015-09-01	2017-03-09	(주) 원메디칼	전기화학적 검출방법에 의한 알레르겐 검출 장치
CN106353376A (zh) *	2016-08-30	2017-01-25	南京师范大学	一种β‑肾上腺受体激动剂多残留检测电化学传感器及其检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2706067B1 (fr) *	1993-06-03	1995-07-07	Commissariat Energie Atomique	Polymère conducteur dopé par un sel de cyclodextrine sulfonée et dispositif pour capter et/ou délivrer une substance active, comportant ce polymère.
US6582583B1 (en) *	1998-11-30	2003-06-24	The United States Of America As Represented By The Department Of Health And Human Services	Amperometric biomimetic enzyme sensors based on modified cyclodextrin as electrocatalysts
AT408662B (de) *	2000-05-16	2002-02-25	Hoffmann La Roche	Creatinin-sensor
CA2578227A1 (fr) *	2004-08-24	2006-11-30	University Of South Florida	Membrane polymere amelioree par resine epoxyde, pour augmenter la longevite de capteurs biologiques

2008
- 2008-11-10 IE IES20080900 patent/IES20080900A2/en not_active Application Discontinuation
2009
- 2009-11-10 WO PCT/EP2009/064942 patent/WO2010052342A2/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2010052342A3 (fr)	2010-07-15
WO2010052342A2 (fr)	2010-05-14

Publication	Publication Date	Title
Baluta et al.	2022	Differential pulse voltammetry and chronoamperometry as analytical tools for epinephrine detection using a tyrosinase-based electrochemical biosensor
GhavamiNejad et al.	2023	A conductive hydrogel microneedle‐based assay integrating PEDOT: PSS and Ag‐Pt nanoparticles for real‐time, enzyme‐less, and electrochemical sensing of glucose
Thakur et al.	2021	Ultrasensitive electrochemical biosensors for dopamine and cholesterol: recent advances, challenges and strategies
Feng et al.	2019	Low-fouling nanoporous conductive polymer-coated microelectrode for in vivo monitoring of dopamine in the rat brain
Wang et al.	2011	Au-nanoclusters incorporated 3-amino-5-mercapto-1, 2, 4-triazole film modified electrode for the simultaneous determination of ascorbic acid, dopamine, uric acid and nitrite
Uang et al.	2003	Fabrication of glucose oxidase/polypyrrole biosensor by galvanostatic method in various pH aqueous solutions
Peltola et al.	2018	Electrochemical fouling of dopamine and recovery of carbon electrodes
Xiao et al.	2017	In vivo analysis with electrochemical sensors and biosensors
Yang et al.	2014	High-performance conducting polymer nanofiber biosensors for detection of biomolecules
Wang et al.	2014	Enhanced catalytic and dopamine sensing properties of electrochemically reduced conducting polymer nanocomposite doped with pure graphene oxide
Jiang et al.	2016	Novel modifications to carbon-based electrodes to improve the electrochemical detection of dopamine
Vreeland et al.	2015	Biocompatible PEDOT: Nafion composite electrode coatings for selective detection of neurotransmitters in vivo
Wang et al.	2019	Improvement of the biocompatibility and potential stability of chronically implanted electrodes incorporating coating cell membranes
Wu et al.	2018	Highly sensitive and stable zwitterionic poly (sulfobetaine-3, 4-ethylenedioxythiophene)(PSBEDOT) glucose biosensor
Fu et al.	2018	A solid-state electrochemical sensing platform based on a supramolecular hydrogel
Ates et al.	2008	Carbon fiber microelectrodes electrocoated with polycarbazole and poly (carbazole-co-p-tolylsulfonyl pyrrole) films for the detection of dopamine in presence of ascorbic acid
Eom et al.	2022	Highly conductive polydopamine coatings by direct electrochemical synthesis on Au
Türkarslan et al.	2009	A new amperometric cholesterol biosensor based on poly (3, 4-ethylenedioxypyrrole)
Liu et al.	2023	Implantable electrochemical sensors for brain research
Sriprasertsuk et al.	2021	Polypyrrole-coated carbon fibre electrodes for paracetamol and clozapine drug sensing
Senel et al.	2020	Enhanced electrochemical sensing performance by in situ electrocopolymerization of pyrrole and thiophene-grafted chitosan
Hernández‐Jiménez et al.	2016	Voltammetric determination of metronidazole using a sensor based on electropolymerization of α‐cyclodextrin over a carbon paste electrode
Cho et al.	2020	Timed electrodeposition of PEDOT: Nafion onto carbon fiber-microelectrodes enhances dopamine detection in zebrafish retina
US20100116655A1 (en)	2010-05-13	Chemical messenger sensor
Wang et al.	2012	Glassy carbon electrode modified with poly (dibromofluorescein) for the selective determination of dopamine and uric acid in the presence of ascorbic acid

Legal Events

Date	Code	Title	Description
2010-12-08	FJ9A	Application deemed to be withdrawn section 31(3)